Of the 267 BRCA1/2 carriers, 183 (68.5%) received the clinically confirmed result through an electronic health record portal and were offered clinical risk management. In total, 84 participants withdrew from the study, died, or did not update their consent; these cases had only deidentified records and were not eligible for returned results.
A, Relevant cancers in this analysis included breast, ovarian, prostate, pancreatic, and melanoma. BRCA1/2 controls included individuals without pathogenic and likely pathogenic BRCA1/2 variants. BRCA1/2 cases included BRCA1/2 carriers. Health system patients also included those who did not undergo screening. Mantel-Haenszel test was used to determine the fixed-effects odds ratio.
eTable 1. List of All Pathogenic and Likely Pathogenic Variants in BRCA1 and BRCA2 That Were Identified in Cohort
eTable 2. The Overall Prevalence and Prevalence Controlling for Relatedness
eTable 3. Cause of Death Analysis
eTable 4. Relevant Cancer Among the Living Cases
eTable 5. Table Demonstrating Groupings for Odds Ratio Calculations for Figure 2B-D
eFigure 1. Pedigree and Case Story
eFigure 2. Family Health History in EHR of BRCA1/2 Cases (Women and Men)
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Manickam K, Buchanan AH, Schwartz MLB, et al. Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Netw Open. 2018;1(5):e182140. doi:10.1001/jamanetworkopen.2018.2140
Can population-level genomic screening identify those at risk for disease?
In this cross-sectional study of an unselected population cohort of 50 726 adults who underwent exome sequencing, pathogenic and likely pathogenic BRCA1 and BRCA2 variants were found in a higher proportion of patients than was previously reported.
Current methods to identify BRCA1/2 variant carriers may not be sufficient as a screening tool; population genomic screening for hereditary breast and ovarian cancer may better identify patients at high risk and provide an intervention opportunity to reduce mortality and morbidity.
Detection of disease-associated variants in the BRCA1 and BRCA2 (BRCA1/2) genes allows for cancer prevention and early diagnosis in high-risk individuals.
To identify pathogenic and likely pathogenic (P/LP) BRCA1/2 variants in an unselected research cohort, and to characterize the features associated with P/LP variants.
Design, Setting, and Participants
This is a cross-sectional study of adult volunteers (n = 50 726) who underwent exome sequencing at a single health care system (Geisinger Health System, Danville, Pennsylvania) from January 1, 2014, to March 1, 2016. Participants are part of the DiscovEHR cohort and were identified through the Geisinger MyCode Community Health Initiative. They consented to a research protocol that included sequencing and return of actionable test results. Clinical data from electronic health records and clinical visits were correlated with variants. Comparisons were made between those with (cases) and those without (controls) P/LP variants in BRCA1/2.
Prevalence of P/LP BRCA1/2 variants in cohort, proportion of variant carriers not previously ascertained through clinical testing, and personal and family history of relevant cancers among BRCA1/2 variant carriers and noncarriers.
Of the 50 726 health system patients who underwent exome sequencing, 50 459 (99.5%) had no expected pathogenic BRCA1/2 variants and 267 (0.5%) were BRCA1/2 carriers. Of the 267 cases (148 [55.4%] were women and 119 [44.6%] were men with a mean [range] age of 58.9 [23-90] years), 183 (68.5%) received clinically confirmed results in their electronic health record. Among the 267 participants with P/LP BRCA1/2 variants, 219 (82.0%) had no prior clinical testing, 95 (35.6%) had BRCA1 variants, and 172 (64.4%) had BRCA2 variants. Syndromic cancer diagnoses were present in 11 (47.8%) of the 23 deceased BRCA1/2 carriers and in 56 (20.9%) of all 267 BRCA1/2 carriers. Among women, 31 (20.9%) of 148 variant carriers had a personal history of breast cancer, compared with 1554 (5.2%) of 29 880 noncarriers (odds ratio [OR], 5.95; 95% CI, 3.88-9.13; P < .001). Ovarian cancer history was present in 15 (10.1%) of 148 variant carriers and in 195 (0.6%) of 29 880 variant noncarriers (OR, 18.30; 95% CI, 10.48-31.4; P < .001). Among 89 BRCA1/2 carriers without prior testing but with comprehensive personal and family history data, 44 (49.4%) did not meet published guidelines for clinical testing.
Conclusions and Relevance
This study found that compared with previous clinical care, exome sequencing–based screening identified 5 times as many individuals with P/LP BRCA1/2 variants. These findings suggest that genomic screening may identify BRCA1/2-associated cancer risk that might otherwise remain undetected within health care systems and may provide opportunities to reduce morbidity and mortality in patients.
Pathogenic variants in the BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) genes were first associated with familial breast cancer risk in the mid-1990s.1,2 Associated risks for ovarian cancer, prostate cancer, pancreatic cancer, and melanoma have since been documented; these clinical associations are grouped as hereditary breast and ovarian cancer (HBOC) syndrome.3
Clinical testing for pathogenic variants in the BRCA1 and BRCA2 (ie, BRCA1/2) gene became available in 1995.4 Risk-assessment strategies, based on personal and family history cancer thresholds, have been built, validated, and incorporated into clinical testing guidelines. These guidelines are routinely used to identify individuals with increased pretest probability of pathogenic BRCA1/2 variants.5,6 Current established guidelines have been issued by the National Comprehensive Cancer Network (NCCN),7 the US Preventive Services Task Force,8 and the American College of Medical Genetics and Genomics together with the National Society of Genetic Counselors.9
Clinical underascertainment of individuals with pathogenic BRCA1/2 variants may be associated with the failure to apply testing guideline criteria and the failure of criteria-based strategies to identify all true positives.10,11 Such underascertainment has been documented even in women with existing cancer diagnoses12,13 and has prompted calls for DNA sequence–based population screening.14
In this article, we report the pathogenic variants prevalence, HBOC syndrome–associated cancer history, and comparison of exome sequencing–based screening with indication-based ascertainment in a cross-sectional study of predominantly white (European ancestry) adults who underwent exome sequencing at a single US health care system (Geisinger Health System, Danville, Pennsylvania) from January 1, 2014, to March 1, 2016. These individuals had “expected pathogenic” (ie, known pathogenic and likely pathogenic) BRCA1/2 variants identified by exome sequencing. Sequencing-based screening findings were ascertained independent of participants’ age, sex, or cancer history.15 The cases and controls are part of the ongoing DiscovEHR cohort and were identified through the Geisinger MyCode Community Health Initiative. This large exome-sequenced research cohort has a median of 14 years of linked electronic health records (EHRs), and the patients consented to a research protocol that included sequencing and return of actionable test results.15,16 The genomic findings were confirmed by clinical laboratory testing and entered into the EHR.
This cross-sectional study received approval from Geisinger Institutional Review Board. Written informed consent was obtained from participants. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Cases are defined as individuals with a pathogenic or likely pathogenic (P/LP) variant in either the BRCA1 or BRCA2 gene. We referred to these cases as BRCA1/2 carriers to be consistent with published literature. Controls are defined as the participants who underwent sequencing in the biobank (MyCode; Geisinger) and screened negative for P/LP variants in both the BRCA1 and BRCA2 genes. We further subdivided the case population on the basis of (1) prior identification of a variant, (2) personal or family history that would have met established clinical criteria for referral or testing, and (3) gene involvement.
For the purposes of this article, an HBOC syndrome diagnosis was assigned in cases in which both genotype and phenotype were present. Therefore, HBOC syndrome diagnosis refers to cases in which a relevant cancer occurred (ie, BRCA1/2 carriers whose genetic risk was associated with personal history of relevant cancer at any age). The relevant cancers included breast, ovarian, prostate, pancreatic, and melanoma.
The biobank and the associated clinical return of results were approved by the Geisinger Institutional Review Board.16 Enrollment in the biobank by written informed consent began on January 1, 2007. Participants who consented prior to October 1, 2013, did not explicitly agree to have their genomic results returned to their health care practitioner and entered into the EHR; these were considered outdated consents and not eligible for clinical result return if efforts to reconsent were unsuccessful. Individuals with outdated consents are included in the biobank’s data analysis.
Analysis for this article was limited to 50 726 health system patients who underwent exome sequencing as participants in the biobank, aged 18 years or older, with EHR data, and with whole exome sequencing data available through the DiscovEHR study.15 Additional details on the biobank study design, EHR data extraction, and sequenced data characteristics have been previously described.15,16
The BRCA1/2 carrier subgroup who had undergone prior clinical BRCA1/2 testing was significantly younger and had an overrepresentation of women when compared with BRCA1/2 carriers without prior testing (Table 1).
The American College of Medical Genetics and Genomics criteria for variant classification was established to more uniformly categorize variants on the basis of standardized criteria.17 Using conservative interpretation to reduce false-positives, we identified BRCA1/2 carriers with expected pathogenic variants on the basis of (1) classification in ClinVar with a *2 or *3 status, indicating strong evidence for pathogenicity18; (2) predicted loss of function; or (3) both (eTable 1 in the Supplement). For identified cases, we sent a DNA sample to the Clinical Laboratory Improvement Amendments–certified Laboratory for Molecular Medicine at Partners HealthCare for clinical variant interpretation and Sanger confirmation prior to clinical result return. Benign variants and variants of unknown significance were not returned. All confirmed P/LP variants are deposited in ClinVar per Laboratory for Molecular Medicine protocol.
We used identity by descent analysis to determine if relatedness contributed to observed prevalence (eTable 2 in the Supplement).19 For high-level analysis, we compared data, including demographic information and cancer diagnoses, with the EHR data of the general health system population, but the primary analysis involved a comparison of cases and controls from the biobank population.
Primarily, HBOC syndrome refers to patients who have a relevant cancer and identification as P/LP BRCA1/2 carrier, but in the case of screening (both familial carrier testing and population level), this application is not sufficient. Therefore, we employed a previously described diagnostic framework for incidental or secondary genomic findings. The framework’s 5 diagnostic groups include 3 groups with relevant cancer diagnoses (ie, clinical findings consistent with the genomic risk result are present) and in which the conventional diagnosis of HBOC is made as well as 2 groups in which relevant clinical findings are absent in the participants (Table 2). Diagnostic disposition was assigned after a clinical evaluation, when possible, associated with the return of results; alternatively, EHR data were used.
Clinical laboratory reports were entered into the EHR of 183 of 267 (68.5%) BRCA1/2 carriers (Figure 1) between May 1, 2015 and June 30, 2017. These participants were then (1) supported to pursue NCCN guidelines–based clinical management7,21 and (2) encouraged to complete a targeted 3-generation family history (either in person or online). Each pedigree was independently analyzed by at least 2 licensed genetic counselors (A.H.B., M.L.B.S., M.L.G.H., J.L.W., A.K.R., H.R., and J.M.S.), who assessed threshold criteria for referral and testing according to the guidelines of the NCCN,7 US Preventive Services Task Force,8 and American College of Medical Genetics and Genomics–National Society of Genetic Counselors.9 Discordance between the reviewers was resolved by joint review and consensus. A total of 122 relevant 3-generation pedigrees were analyzed, of which 89 (72.9%) were from participants who had not undergone prior BRCA1/2 clinical testing (Table 3).
Twenty participants died before their result became available, and 3 died after the return of result (before June 30, 2017). Medical record review was carried out by 3 clinicians (K.M., D.M.L., and M.F.M.) independently and then jointly to determine the cancer diagnosis and cause of death (eTable 3 in the Supplement).
Data were summarized using means and ranges for continuous variables as well as frequencies and percentages for categorical variables. Comparisons between groups were performed using Wilcoxon rank sum test, Pearson χ2 test, and 2-sided Fisher exact test, as appropriate. Logistic regression was used to estimate odds ratios (ORs) and 95% CIs. Two-sided P < .05 was considered statistically significant. All analyses were performed using SAS, version 9.4 (SAS Institute Inc).
Of the 50 726 health system patients who underwent whole exome sequencing, 50 459 (99.5%) had no expected pathogenic BRCA1/2 variants and 267 (0.5%) were BRCA1/2 carriers. Of the 267 cases (148 [55.4%] were women and 119 [44.6%] were men with a mean [range] age of 58.9 [23-90] years), 183 (68.5%) received clinically confirmed results in their EHR. Compared with the health system’s overall population, the biobank cohort was older (mean [range] age, 50.1 [18-89] years vs 59.9 [18-89] years; P < .001), had a greater percentage of women (668 483 [53.4%] vs 29 880 [59.2%]; P < .001), had a higher representation of white patients (1 159 920 [92.6%] vs 49 623 [98.3%]; P < .001), and was enriched for relevant cancers (862 [1.7%] vs 1254 [0.10%]; P < .001).
The prevalence of participants with a Sanger sequencing–confirmed P/LP BRCA1/2 variants was 1:190, and 1:180 when controlling for relatedness (eTable 2 in the Supplement). Ninety-five patients (35.6%) were identified with BRCA1 variants, and 172 patients (64.4%) had BRCA2 variants. There were 118 P/LP variants in BRCA1/2 in the 267 carriers (eTable 1 in the Supplement). Of the 118 variants, 113 (95.8%) were previously classified in ClinVar: 103 P/LP with a *2 or *3 status,18 5 P/LP by a single laboratory, 1 variant of unknown significance, and 4 with conflicting interpretation entries. Pathogenic or likely pathogenic vs variant of unknown significance interpretations agreed with 99.1% (108 of 109) of the existing clinical significance designations in ClinVar; the single difference was 1 listed in ClinVar as variant of unknown significance that was designated as LP on the basis of updated information.
Of the 52 BRCA1 and 66 BRCA2 variants, 107 (90.67%) were putative loss-of-function variants (66 frameshift, 31 nonsense, and 10 splice variants) and only 5 (4.2%) were novel predicted loss-of-function variants. Eleven of 118 variants (9.3%) were missense, and no novel missense variants were classified as P/LP, in accordance with the criteria set forth by the American College of Medical Genetics and Genomics for variants interpretation.17
Sanger sequencing confirmed 267 bioinformatically identified BRCA1/2 carriers and ruled out 1 candidate carrier as a false-positive. The number of BRCA1/2 carriers with any given variant ranged from 1 to 24 (eTable 1 in the Supplement). Most variants (74 of 118 [62.7%]) were only seen in 1 carrier. Two well-documented common US BRCA2 pathogenic variants (ClinVar variation ID: 38082 and 9320)2,22 accounted for 42 BRCA1/2 carriers, and 1 of 3 Ashkenazi Jewish founder mutations was found in 19 BRCA1/2 carriers.3
Forty-eight (17.9%) of the 267 BRCA1/2 carriers were already aware of their result through prior clinical BRCA1/2 testing; these were patients who were diagnosed on the basis of traditional detection methods such as personal and family history. Newly diagnosed BRCA1/2 carriers (without prior clinical testing) were more likely than controls (without BRCA1/2 variants) to have EHR evidence of personal or family history of HBOC syndrome–associated cancer diagnoses (28.0% vs 53.4%) (Figure 2A and eTable 5 in the Supplement). New carriers were significantly more likely to have had breast cancer, ovarian cancer, and family history of any HBOC syndrome–associated cancer (Figure 2B-D). In 219 (82.0%) BRCA1/2 carriers without prior clinical BRCA1/2 testing compared with controls, the OR for personal history of any HBOC syndrome–associated cancer was 2.32 (95% CI, 1.63-3.29; P < .001), indicating significantly increased cancer risk associated with the BRCA1/2 carriers ascertained in this fashion.
Syndromic cancer diagnoses were present in 11 (47.8%) of the 23 deceased BRCA1/2 carriers and in 56 (20.9%) of all 267 BRCA1/2 carriers. Among women, 31 (20.9%) of 148 variant carriers had a personal history of breast cancer, compared with 1554 (5.2%) of 29 880 noncarriers (OR, 5.95; 95% CI, 3.88-9.13; P < .001). Ovarian cancer history was present in 15 (10.1%) of 148 variant carriers and in 195 (0.6%) of 29 880 variant noncarriers (OR, 18.30; 95% CI, 10.48-31.4; P < .001).
Primarily because of outdated consent, not all participants were eligible to receive results (Figure 1). Of 267 BRCA1/2 carriers, results were returned to 183 eligible adults (68.5%) and their health care practitioner through a secure EHR portal; this was followed up by a letter and telephone call to the participants. Clinical care based on NCCN guidelines7 was offered, and 3 examples of early cancer detection were described in a report.21 A case of a woman in her 40s with subclinical disease detected on screening was identified after that report (eFigure 1 in the Supplement).
Analysis of the pedigrees of the 122 carriers on whom we had sufficient personal and family cancer history is found in Table 3. Among the criteria-based assessment tools, the NCCN criteria appeared to be the most sensitive, with 63% of pedigrees meeting the guidelines for testing. Of the 33 individuals who had prior testing, 32 (96.9%) met the NCCN criteria; of the 89 individuals who had not had prior testing, 45 (50.5%) met the criteria and 44 (49.4%) did not meet the criteria. Across all carriers, 34 (77.2%) of 44 BRCA1 carriers and 43 (55.1%) of 78 BRCA2 carriers met the NCCN criteria. In nearly every category, women were more likely than men to meet criteria thresholds (Table 3) on the basis of relevant cancer diagnosis (22 of 70 [31.4%] had personal history); underreporting of family health history in men appears to be a contributing factor in this observation (eFigure 2 in the Supplement).23
The participants’ final diagnostic category was based on all relevant clinical information reviewed, including the EHR and participant self-report when available (Table 2). The HBOC syndrome diagnosis, assigned in individuals with both P/LP variants and a relevant cancer, constitutes groups 1, 2, and 3 (Table 2) using the groupings for incidental or secondary genomic findings.20 The diagnosis was made in 52 (19.5%) of all cases (39 [26.4%] of women; 13 [10.9%] of men).
Twenty-three (8.6%) of 267 participants were deceased by June 1, 2017, and the median age at death was 64.7 years (eTable 3 in the Supplement). Twenty participants died prior to the return of results, and 3 died after the return of results. The observed lifetime occurrence of any relevant cancers in the 23 deceased participants was 47.8% (75.0% in women; 18.2% in men). Among the 23 deaths, the cause of death was determined to be BRCA1/2-associated cancer in 9 people (39.1%), unrelated to BRCA1/2 in 11 (47.8%), and indeterminate in 3 (13.0%). In contrast to the deceased cases, 45 (18.4%) of 244 living patients have a personal history of a relevant cancer (eTables 3 and 4 in the Supplement).
Findings demonstrate that routine exome sequencing–based screening may be a potential factor in long-term care improvement. This study found that only 17.9% of BRCA1/2 carriers had prior BRCA1/2 clinical genetic testing in the course of their ongoing health care. In addition, in the subcohort of 89 individuals without prior testing but with detailed personal and family history data, 45 (50.5%) met current NCCN criteria for testing but had not received testing; conversely, 44 individuals (49.4%) did not meet NCCN testing criteria but had expected pathogenic variants. Of importance, those patients who did not meet the established thresholds for BRCA1/2 testing were not spared from relevant cancers, as evidenced by the diagnosis of early asymptomatic cancer in such individuals after the initiation of cancer risk management.21
Our evidence demonstrates that this clinical underascertainment may be associated with both the failure to apply criteria-based referral for BRCA1/2 testing strategies to individuals with high pretest probabilities and the failure of such criteria-based strategies to be sufficiently sensitive to identify all true positives. The practical difficulties of incorporating sufficient family history risk analysis in routine health care settings are well described.24 The observed gap in relevant cancer history between all living BRCA1/2 carriers and deceased BRCA1/2 carriers signals an opportunity to prospectively identify and manage individuals with elevated risk to reduce the morbidity and mortality associated with their defined cancer risk. Early success in this area is demonstrated by the identification of 4 individuals with early-stage cancer during the screening and management recommended by the exome sequencing–based screening results process.
Our findings show considerable clinical underascertainment of individuals with HBOC syndrome. Underascertainment has also been observed in familial hypercholesterolemia and Lynch syndrome, 2 conditions that (along with HBOC syndrome) are designated as tier 1 (ie, disease with available evidence-based guidelines and recommendations that potentially positively affect public health) by the Centers for Disease Control and Prevention Office of Public Health Genomics and are included in the Healthy People 2020 recommendations.25,26 Underascertainment of these conditions, in which presymptomatic case identification is advantageous,21,25 should prompt prioritization of further research into genomic sequencing–based population screening.27
Overall, ascertainment through sequencing-based screening in the biobank cohort showed an empirical prevalence for BRCA1/2 expected pathogenic variants of 1:190, adjusted to 1:180 when controlling for relatedness up to the third degree.19,25 Consistent with other studies, HBOC syndrome–associated cancer rates were higher in women than in men and in BRCA1 carriers than in BRCA2 carriers.3,28 Unsurprisingly, those with prior clinical BRCA1/2 testing also had higher cancer rates than those without prior testing. For the subset of 23 deceased BRCA1/2 carriers, only 4 had prior clinical testing and the percentage with syndromic cancer diagnoses was 47.8%, which is similar to published observations of clinically ascertained cases.3
The observed BRCA1 to BRCA2 case ratio of 1.0:1.8 is consistent with ratios in other relevant work.29-31 Previous research3 shows decreased penetrance for BRCA2 carriers, which may be a contributing factor in the underascertainment of these cases compared with BRCA1 cases; in our study, among those with prior testing and cancer diagnosis, more than 90% had BRCA1-associated cancer risk.
Among the 82.1% of BRCA1/2 carriers who did not have prior clinical BRCA1/2 testing, the return of genomic result was the start of a diagnostic process aimed at deciding if the risk variants were associated with current or past disease.20 For those with a personal history of BRCA1/2-associated cancer, a diagnosis of HBOC syndrome was now clear and the recommended management was changed to align with NCCN guidelines and to offer cascade testing for at-risk family members. Those without BRCA1/2-associated cancer at results disclosure did not have a diagnosis of HBOC syndrome, and long-term risk-reduction measures were recommended. For individuals with risk variants but without disease, the variants result was listed in their EHR problem list as a test result and not as an HBOC syndrome diagnosis.20,32 This distinction is important because continued surveillance is recommended, but syndrome diagnosis may not ever be achieved.20,25,32
Substantial infrastructure and health care practitioner collaboration were necessary to support the disclosure and follow-up care of the 183 participants whose biobank consent form allowed for clinical reporting.32 Consistent with the vision of learning health care systems,33-35 this disclosure and follow-up approach is being informed and improved by ongoing feedback from biobank participants, health care practitioners, and researchers. In addition, the disclosure can be used as a template for other settings where the genome-first care model is implemented.
Finally, optimal clinical management of patients identified through sequencing-based screening who do not otherwise meet the criteria for clinical testing is likely to evolve as more longitudinal outcomes data become available from this cohort and others. Given a near-term gap in evidence-based management, patients at Geisinger receive management based on previously developed protocols for BRCA1/2-positive individuals,7 but patients are informed that important knowledge gaps exist. The capture and aggregation of health outcomes data from this and other cohorts is essential to developing evidence that guides precision management strategies for individuals identified through whole exome sequencing–based screening.36 These health outcomes data, coupled with analysis of the cost of care (including cost of testing, counseling, and interventions), will ultimately determine the value of exome sequencing–based screening and inform the implementation of screening strategies for the BRCA1/2 variants.
In general, the participants in the biobank were older than the health system’s patient population; more important, this study skewed toward those who received regular health care, increasing their opportunity to be enrolled in the biobank research. The higher incidence of breast cancer in the biobank population was likely a reflection of frequency of care and age; however, in our risk analysis, we used the biobank patients without evidence of BRCA1/2 variants as the control population, which mitigated this bias.
The study still likely underestimated prevalence in this health care system–based cohort because of the (1) limitations to the current variant identification strategy (eg, our protocol did not include deletion-duplication analysis, which accounts for 10% of clinical variants)3; (2) absence of attempts to assign significance to missense variants beyond that established in ClinVar, and (3) estimated underrepresentation of cases with early-onset disease in the study cohort as a result of HBOC syndrome–associated mortality, given the age difference between the BRCA1/2 cohort and the general health system population.37 The first 2 issues will be addressed in future work. We recognize that, because this study population is reflective of the local population and thus is overwhelmingly white,16 it may not be representative of other cohorts, particularly those from different racial/ethnic backgrounds. As with many areas of genomic medicine implementation, inclusion of greater numbers of individuals from underrepresented race/ethnicity is essential to a complete understanding of BRCA1/2 risk.38 Data from other cohorts will be needed to clarify whether this BRCA1 to BRCA2 ratio finding is generalizable for population screening.
The prevalence of BRC1/2 variants in the general population may be substantially higher than was previously estimated, and reliance on personal and family history may be an inadequate measure to ascertain risk for BRCA1/2 variants.
Accepted for Publication: June 27, 2018.
Published: September 21, 2018. doi:10.1001/jamanetworkopen.2018.2140
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Manickam K et al. JAMA Network Open.
Corresponding Author: Michael F. Murray, MD, Department of Genetics, Yale School of Medicine, 333 Cedar St, New Haven, CT 06510 (firstname.lastname@example.org).
Author Contributions: Dr Murray had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Manickam, Schwartz, J. L. Williams, Lindbuchler, Giovanni, M. S. Williams, Ledbetter, Murray.
Acquisition, analysis, or interpretation of data: Manickam, Buchanan, Schwartz, Hallquist, Rahm, Rocha, Savatt, Evans, Butry, Lazzeri, Flansburg, Leeming, Vogel, Lebo, Mason-Suares, Hoskinson, Abul-Husn, Dewey, Overton, Reid, Baras, Willard, McCormick, Krishnamurthy, Hartzel, Kost, Lavage, Sturm, Frisbie, Person, Metpally, Giovanni, Lowry, Leader, Ritchie, Carey, Justice, Kirchner, Faucett, M. S. Williams, Ledbetter, Murray.
Drafting of the manuscript: Manickam, Hallquist, Rocha, Evans, Butry, Lazzeri, Lindbuchler, Lavage, Frisbie, Murray.
Critical revision of the manuscript for important intellectual content: Manickam, Buchanan, Schwartz, Hallquist, J. L. Williams, Rahm, Savatt, Flansburg, Leeming, Vogel, Lebo, Mason-Suares, Hoskinson, Abul-Husn, Dewey, Overton, Reid, Baras, Willard, McCormick, Krishnamurthy, Hartzel, Kost, Sturm, Person, Metpally, Giovanni, Lowry, Leader, Ritchie, Carey, Justice, Kirchner, Faucett, M. S. Williams, Ledbetter, Murray.
Statistical analysis: Butry, Person, Kirchner, Murray.
Obtained funding: J. L. Williams, Baras, McCormick, Giovanni, Faucett, Ledbetter, Murray.
Administrative, technical, or material support: Manickam, Buchanan, Schwartz, Hallquist, J. L. Williams, Rahm, Evans, Butry, Lazzeri, Lindbuchler, Flansburg, Vogel, Lebo, Mason-Suares, Overton, Reid, Willard, McCormick, Lavage, Sturm, Frisbie, Person, Giovanni, Carey, Ledbetter.
Supervision: Manickam, Lebo, Hoskinson, McCormick, Faucett, M. S. Williams, Ledbetter, Murray.
Conflict of Interest Disclosures: Ms J. L. Williams reported receiving grants from the National Human Genome Research Institute (NHGRI) during the conduct of the study. Dr Rahm reported receiving grants from NHGRI and from Regeneron Pharmaceuticals during the conduct of the study. Ms Flansburg reported receiving grants from Regeneron Genetics Center during the conduct of the study. Dr Vogel reported receiving grants from Regeneron Pharmaceuticals during the conduct of the study. Dr Lebo reported receiving grants from the National Institutes of Health (NIH)/NHGRI during the conduct of the study. Dr Baras reported being an employee of Regeneron Genetics Center outside of the submitted work. Mr Hartzel reported receiving compensation as an analyst through funding received by Geisinger from Regeneron Pharmaceuticals. Mr Lavage reported receiving compensation as an analyst through funding received by Geisinger from Regeneron Pharmaceuticals. Dr Ritchie reported receiving grants from Regeneron Genetics Center during the conduct of the study. Dr Kirchner reported receiving grants from Regeneron Pharmaceuticals during the conduct of the study. Mr Faucett reported receiving grants from NIH during the conduct of the study. Dr Ledbetter reported receiving grants from Regeneron Biopharmaceuticals during the conduct of the study. Dr Murray reported receiving grants from Regeneron Pharmaceuticals during the conduct of the study as well as personal fees from Invitae outside the submitted work. No other disclosures were reported.
Funding/Support: This study was funded by institutional support from Geisinger and grants from the Horace W. Goldsmith Foundation, the Mericle Foundation, the Robert Wood Johnson Foundation, and the Commonwealth of Pennsylvania Department of Community and Economic Development.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the more than 150 000 individuals who provided consent to MyCode and participated in this research. We also thank the MyCode leadership, in particular Glenn D. Steele, Jr, MD, PhD, and David T. Feinberg, MD, MBA, at Geisinger. We are grateful for the rigor and responsiveness exhibited by our bioinformatics colleagues at the Laboratory for Molecular Medicine, particularly Christina Austin-Tse, PhD, and Heidi L. Rehm, PhD. Finally, we thank the staff of Geisinger Clinical Genomics and the Inherited Risk Breast Clinic for helping to coordinate care for individuals with a genomic result. None of the named individuals were financially compensated for their contributions.
Create a personal account or sign in to: